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Cohort profile
AbstrACt 
Purpose Little information is available on patients on 
antiretroviral treatment (ART) after a long-term period from 
sub-Saharan Africa, with the longest follow-up and related 
outcomes being after 10 years on ART. At the Infectious 
Diseases Institute (IDI) (Kampala, Uganda), we set up a 
cohort of patients already on ART for 10 years at the time 
of enrolment, who will be followed up for additional 10 
years.
Participants A prospective observational cohort of 1000 
adult patients previously on ART for 10 years was enrolled 
between May 2014 and September 2015. Patients were 
eligible for enrolment if they were in their consecutive 
10th year of ART regardless of the combination of drugs 
for both first- and second-line ART. Data were collected at 
enrolment and all annual study visits. Follow-up visits are 
scheduled once a year for 10 years. Biological samples 
(packed cells, plasma and serum) are stored at enrolment 
and follow-up visits.
Findings to date Out of 1000 patients enrolled, 345 
(34.5%) originate from a pre-existing research cohort 
at IDI, while 655 (65.5%) were enrolled from the routine 
clinic. Overall, 81% of the patients were on first line at the 
time of the enrolment in the ART long-term cohort, with the 
more frequent regimen being zidovudine plus lamivudine 
plus nevirapine (44% of the cohort), followed by zidovudine 
plus lamivudine plus efavirenz (22%) and tenofovir plus 
lamivudine or emtricitabine plus efavirenz (10%). At cohort 
enrolment, viral suppression was defined as HIV-RNA 
<400 copies/mL was 95.8%.
Future plans Through collaboration with other 
institutions, we are planning several substudies, including 
the evaluation of the risk for cardiovascular diseases, the 
assessment of bone mineral density, screening for liver 
cirrhosis using fibroscan technology and investigation of 
drug–drug interactions between ART and common drugs 
used for non-communicable diseases.
IntroduCtIon  
The scale up and expansion of access 
to antiretroviral treatment (ART) have 
improved the clinical outcomes of HIV-pos-
itive patients in resource-limited settings. 
Overall, programmes have reported a decline 
in mortality1 2 and opportunistic infections,3 
good immune-reconstitution in terms of CD4 
count gain,4 high levels of adherence5 and 
acceptable rates of viral suppression.6 7
To our knowledge, only two analyses have 
reported outcomes of patients on ART up 
to 10 years of follow-up,8 9 and informa-
tion on long-term complications of ART 
and non-HIV-related events is still limited. 
Although data are available from resource-
rich settings, this information may not be 
applicable to sub-Saharan Africa due to the 
different ART drugs used10 and ART moni-
toring strategies,11 different HIV subtypes,12 
as well as ethnicity and endemic diseases.
Concurrent with the second decade of 
ART delivery in sub-Saharan Africa, we set 
up a cohort of ART-experienced patients (on 
ART for 10 years at the time of enrolment), 
at the Infectious Diseases Institute (IDI), 
Kampala, Uganda, who will be followed up 
for additional 10 years. The main objectives 
of this cohort are to determine the incidence 
of long-term side effects and drug toxicity, 
ART durability and development of morbidi-
ties with the emphasis on non-communicable 
diseases.
The aim of this paper is to present the 
scope, the methods and the baseline clinical 
profile of the ART long-term (ALT) cohort.
strengths and limitations of this study
 ► There is a rich range of clinical information collected 
and high quality of the generated data.
 ► The cohort is a research platform for a wide range 
of substudies.
 ► This cohort does not generally represent patients 
started on antiretroviral treatment (ART) but patients 
who after ART initiation have survived and been 
retained in care.
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Methods
organisation and ethics
The team of investigators consists of five physicians, one 
statistician, one data manager and one quality assur-
ance manager; in 2013, the investigators conceived the 
study and sought for institutional and ethical approval. 
The study preparation took place in the first quarter 
of 2014. The study was approved by the research ethics 
committee of the Joint Clinical Research Center. The 
study is registered with Clinical  trials. org (https:// clini-
caltrials. gov/) as ‘Outcomes of HIV Infected Individuals 
after Ten Years on Antiretroviral Treatment’ Protocol 
Record ST/0113/15.
Our work adheres to the ‘Strengthening the Reporting 
of Observational Studies in Epidemiology’ (STROBE) 
recommendations that provide guidance on the reporting 
of cohort studies (see STROBE checklist).
study sIte
The study patients were recruited in the adult HIV clinic 
at IDI. IDI is a centre of excellence13 for HIV treatment 
and prevention with over 30 000 patients ever registered 
in the clinic. Antiretroviral drugs have been provided by 
the Global Fund and the President’s Emergency Plan for 
AIDS Relief starting in 2004. ART is provided and moni-
tored according to the prevailing WHO and/or Uganda 
Ministry of Health guidelines since 2004. First-line ART 
regimens include two nucleoside reverse inhibitors 
(NRTI) combined with a non-nucleoside reverse inhibi-
tors; patients who fail first-line ART receive a second-line 
combination which includes two NRTIs and a protease 
inhibitor for second-line ART.10 14–16
Patients started on ART in the clinic are initially 
followed up monthly for the first year and then, if stable, 
are seen by a doctor every 3 months and in between come 
for monthly drug refill (pharmacy visit). Patients on ART 
were monitored with CD4 count measurement every 6 
months up to December 2014 according to the national 
guidelines; however, ad hoc viral load (VL) testing was 
made available for patients suspected to have treatment 
failure based on WHO suggested immunological criteria. 
The roll out of routine VL monitoring was started in 
Uganda at the end of 2014.
In 2004, 559 consecutive adult patients starting ART 
were enrolled into the IDI research cohort and followed 
up for 10 years; these patients received study visits every 
3 months and in between came monthly only for routine 
clinic visits in the first year and pharmacy visits thereafter. 
For this group of patients, resources were available for 
biannual prospective virological monitoring from study 
enrolment; details and outcomes of this cohort were 
previously described.8 9 17
The patients of the ALT cohort were recruited from 
both the adult HIV clinic and patients discharged from 
the IDI research cohort. This enrolment strategy was 
chosen to include patients whose prior ART had been 
monitored using CD4 counts, which was at the time the 
standard of care, and those monitored through prospec-
tive VL testing, which is considered the gold standard.
Systematic and quality-controlled data electronic 
capture was implemented in 2004, and information 
is collected and stored in the IDI electronic database, 
known as the Integrated Clinic Enterprise Application 
(ICEA). This is an in-house built system based on Micro-
soft.NET technologies, developed in order to ensure a 
high standard of data.18
study design
A prospective closed observational cohort of 1000 patients 
previously on ART for 10 years was enrolled between 
May 2014 and September 2015 and will be followed up 
for 10 years. The sample size was conveniently chosen 
and guided by financial considerations; however, power 
calculations performed a priori showed sufficient power 
to detect potential outcomes of interest even at preva-
lence <5%. Patients were eligible to be enrolled in the 
study if they were at least 18 year old, were willing to partic-
ipate in the study and comply with the study procedures, 
and were in their consecutive 10th year of ART regardless 
of the combination of drugs for both first- and second-
line ART. Ten-year consecutive ART use was determined 
using the data collected in ICEA.
Subjects were excluded from the study if they had been 
previously enrolled in clinical trials requiring drugs or 
combinations different from those recommended by 
the WHO guidelines, had been on ART before enrolling 
for care at IDI (given the limited reliability or lack of 
information about their medical and ART history prior 
to registration at IDI) and if at any point were lost to 
follow-up, defined as not returning to the clinic for 
either doctor visit or pharmacy refill for more than 3 
months.
study procedures
A list of all eligible patients by ART duration in the 
adult HIV clinic was generated from the database; 2232 
patients were identified, and their clinic files were flagged 
using designated stickers. All patients (354) discharged 
from the IDI research cohort had accrued 10 years on 
ART, and they were therefore eligible for the study. All 
patients from the IDI research cohort and all consecutive 
eligible subjects who presented for their appointment at 
the clinic were offered screening to ascertain all inclu-
sion criteria were met, and to rule out exclusion criteria. 
Eligible subjects who were willing to participate in the 
study provided written consent and were enrolled in the 
study on the same day.
General medical history, physical examination, adher-
ence to ART and prescription of drugs are performed at 
enrolment and all study visits. Follow-up visit are sched-
uled once a year for 10 years; in addition to study visits, 
the participants attend the general clinic every 3 months 
to pick up their ART and concomitant medications. 
Antiretroviral drugs are prescribed according to the 
WHO guidelines; patients with two consecutive VL >1000 
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copies are consider to have treatment failure and deemed 
to be eligible for treatment switch.
Laboratory tests are performed at the Makerere Univer-
sity-John Hopkins University (MUJHU) Core Laboratory 
hosted at IDI and include urine analysis, haemoglobin, 
alanine aminotransferases, CD4 count and HIV VL. The 
following tests are performed only when required: full 
blood count if haemoglobin <10 g/dL, electrolytes and 
blood sugar if proteinuria or glucose is detected in the 
urine analysis and pregnancy test if the last menstrual 
period occurred more than 30 days prior to the study 
visit. Biological samples are processed and stored by the 
IDI research translational laboratory as follows: at enrol-
ment packed cell pellets (five aliquots), plasma (four 
aliquots) and serum (four aliquots); during follow-up, 
plasma (one aliquot) and serum (three aliquots). Funds 
will be sought for additional procedures and laboratory 
testing on the stored samples such as, but not limited, to 
metabolic markers, resistance testing and drug levels.
data collection
Real-time data entry into ICEA is performed by the 
respective providers. Laboratory results performed in the 
MUJHU Core Laboratory are entered into the laboratory 
electronic database and are automatically downloaded 
daily into the ICEA database.
The questionnaires were designed by the study inves-
tigators. Variables collected include basic demographic 
and epidemiological data, clinical history, present clinical 
information including vital signs and body weight, haema-
tological and chemistry laboratory results, medications, 
ART regimen, adherence to ART, drug toxicities, quality 
of life and sexual behaviour. Details of these variables are 
presented in table 1.
All the data collected into ICEA are validated by a quality 
control officer who ensures that the data are complete 
and consistent.
data availability and collaborations
Proposals for use of the ALT cohort data can be 
submitted to the investigators committee for review 
of the analysis plan and for scientific advice. Scientists 
intending to use data of the ALT cohort can access the 
data after signing a data sharing agreement and must 
conduct the analysis in collaboration with the inves-
tigators. The study is also open for external partner-
ships ranging from substudies within the parental ALT 
cohort to collaborations with other cohorts; full written 
proposals are submitted to the investigators committee, 
and on approval, a collaboration agreement must be 
signed by both parties.
definitions and statistical methods
We described patients’ characteristics at the time of 
enrolment in the cohort and at the time of ART start. We 
compared the characteristics of the patients previously 
enrolled and those who were not enrolled in the IDI 
research cohort using χ2 test for proportions and Mann-
Whitney U test for variables not normally distributed. 
Laboratory tests were considered done at time of enrol-
ment at ART start if they were performed within 183 days 
before or within 14 days after the clinic visit.
Table 1 Type and description of the variables collected in ART long-term cohort
Type of variable Variables Visit
Basic 
demographics
Sex, age, physical address and locator form address, phone contact, details and phone 
number of treatment supporter
Enrolment
Epidemiological Tribe, marital status, number of children, income, employment status Enrolment
Clinical history Date and result of HIV-positive result, date of enrolment into care, history opportunistic 
infections and non-communicable diseases, WHO staging, history of hospitalisation, 
smoking (yes/no) and alcohol consumption (yes/no).
Enrolment
ART history Previous ART regimens, ART start and stop date, reason for drug substitution or switch, 
previous ART toxicity and adherence.
Enrolment
Clinical 
information
Present symptoms and duration (days), physical examination Enrolment, 
follow-up
Concomitant 
medications
Cotrimoxazole, fluconazole, isoniazid prophylaxis, antibiotics, anti-malaria and anti-TB 
drugs, medications for diabetes, hypertension drugs, anti-inflammatory, contraceptives, 
chemotherapy
Enrolment, 
follow-up
ART ART regimen, pill count, adherence (analogue visual scale, 7- and 3-day recall), reason for 
missed doses, toxicity, reasons for substitution or switch
Enrolment, 
follow-up
Quality of life Interference of the disease or treatment with daily house and work activities, highest level 
of physical activities, mental status, overall well-being
Enrolment, 
follow-up
Sexual behaviour Knowledge about HIV transmission, number and type of partners in the past year, 
disclosure to partners, partners’ HIV sero-status, contraceptives use, sexually transmitted 
diseases
Enrolment, 
follow-up
Outcomes Date of discharge from the study and reason (death, transfer, loss to follow), verbal autopsy At occurrence
ART, antiretroviral treatment; TB, tuberculosis.
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results
Cohort profile and follow-up
From May 2014 to September 2015, a total of 1000 patients 
were enrolled in the ALT cohort. Of the 354 of the 559 
patients who completed 10 years of follow-up (with the 
others been lost, dead, withdrawn or transferred out8) and 
were discharged from the IDI research cohort (hence-
forth referred as IDI research cohort patients), four died 
and one was transferred out before enrolment in the 
ALT cohort started; of the remaining screened 349, 345 
patients were enrolled in the ALT cohort. Of the 2232 
eligible patients from the routine clinic who had not been 
part of the IDI research cohort (hereafter referred as 
clinic patients), 662 consecutive patients were screened, 
and 655 were enrolled. Reasons for declining to partici-
pate in the study are shown in figure 1.
Figure 1 Screening and enrolment of patients into the cohort.
Table 2 Patients’ characteristics of the ART long-term cohort patients at the time of ART initiation, stratified by enrolment in 
the previous research cohort
Patients’ characteristics
Research cohort, n=345 
(34.5%)
Clinic patients, n=655 
(65.5%) Overall, n=1000 p Value
Sex, female, n (%) 242 (70.1) 377 (57.6) 619 (61.9) <0.001
Age in years, median (IQR) 35 (30–40) 36 (31–41) 36 (31–41) 0.008
WHO stages 3 and 4 310 (89.7) 476 (72.9) 786 (78.8) <0.001
BMI (kg/m2), median (IQR) 20.3 (18.4–22.7) 20.5 (18.8–22.7) 20.3 (18.7–22.7) 0.109
Hb (g/dL), median (IQR) 11.8 (10.5–13.0) 11.4 (10.1–12.9) 11.6 (10.3–12.9) 0.026
CD4 count (cells/µL), median (IQR) 102 (30–168) 66 (24–144) 81 (26–155) 0.004
HIV RNA log10 (copies/mL), median (IQR) 5.44 (5.08–5.74) NA 5.4 (5.08–5.74)
ART regimen*
0.010  Nevirapine 254 (73.6) 548 (83.8) 802 (80.3)
  Efavirenz 91 (26.4) 106 (16.2) 197 (19.7)
*Nevirapine based (nevirapine+stavudine+lavidune); efavirenz based (efavirenz+zidovudine+lamivudine).
All comparisons made using Pearson χ2 test and Wilcoxon rank sum test.
ART, antiretroviral treatment; BMI, body mass index; Hb, haemoglobin; NA, not applicable.
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Table 2 shows the patients characteristics of the ALT 
cohort patients at the time of ART initiation stratified by 
enrolment in the previous research cohort.
Generally, at the time of ART initiation compared 
with clinic patients, the IDI research cohort group had a 
higher proportion of female (70.1% vs 57.6%, p<0.001), 
a higher proportion of patients in WHO stage 3 or 4 
(89.7% vs 72.9%; p<0.001) and a higher proportion of 
patients was started on efavirenz-based regimens (26.4% 
vs 16.2%; p=0.010). Additionally, the IDI research cohort 
patients were younger (median age 35 vs 36; p=0.008), had 
a higher haemoglobin (11.8 vs 11.4 g/dL; p=0026) and 
a higher CD4 count (102 vs 66 cells/µL, p=0.004) as 
compared with the clinic patients.
Table 3 shows the patients characteristics of the ALT 
cohort patients at the time of enrolment in the study strat-
ified by enrolment in the previous research cohort.
Generally, at the time of enrolment in the study, 
compared with clinic patients, the IDI research 
cohort group had a higher proportion of patients 
in WHO stage 3 or 4 (93.3% vs 84.2%; p<0.001), a 
lower haemoglobin (13.4 vs 14.5 g/dL; p<0.001) and a 
higher CD4 count (624 vs 450 cells/µL; p=0.004). We 
observed differences also in the history of opportu-
nistic infections and drug substitution across the two 
groups. There were no differences in the proportion 
of patients on first and second lines between the IDI 
research cohort patients and the clinic patients, as well 
as in the proportion of patients with VL ≥400 copies/
mL at time of enrolment.
Approximately one quarter of the patients had hyper-
tension at the time of enrolment in the ALT cohort; 
hypertension was defined as more than three systolic 
measurements above 140 mm Hg or diastolic measurement 
Table 3 Patients’ characteristics of the ART long-term cohort at cohort enrolment stratified by previous enrolment in the 
Infectious Diseases Institute research cohort
Patients characteristics
Research 
cohort, n=345 (34.5%)
Clinic patients, n=655 
(65.5%) Overall, n=1000 p Value
Sex, female, n (%) 242 (70.1) 377 (57.6) 619 (61.9%) <0.001
Age in years, median (IQR) 45 (40–50) 46 (41–51) 45 (40–51) 0.217
WHO stages 3 and 4 320 (93.3) 549 (84.2) 869 (87.3) <0.001
BMI (kg/m2), median (IQR) 22.4 (19.8–25.0) 22.4 (19.8–25.6 20.3 (18.7–22.7) 0.354
Hb (g/dL), median (IQR) 13.4 (12.5–14.4) 14.5 (13.2–15.9) 14.1 (12.8–15.5) <0.001
CD4 count (cells/µL), median (IQR) 624 (447–773) 450 (329–612) 507(363-680) <0.001
HIV RNA <400 (copies/mL), n (%) 336 (97.4) 622 (95.6) 38 (3.8) 0.148
Median time on ART (months) (IQR) 126 (124–129) 124 (121–127) 125 (122–128) <0.001
History of
  Tuberculosis 48 (13.9) 104 (15.9) 52 (15.2) 0.411
  Cryptococcal meningitis 36 (10.4) 23 (3.5) 59 (5.9) <0.001
  Kaposi’s sarcoma 5 (1.5) 26 (4.0) 31 (3.1) 0.030
  Toxoencephalitis 8 (2.3) 5 (0.80) 13 (1.3) 0.040
  PJP  5 (1.5) 7 (1.1) 12 (1.2) 0.600
ART type 0.934
  First line 282 (81.7) 534 (81.5) 816 (81.6)
  Second line 63 (18.3) 121 (18.5) 184 (18.4)
Number of drug substitutions
  0 74 (21.5) 84 (12.8) 158 (15.8) <0.001
  1–2 126 (36.5) 391 (59.7) 517 (51.7)
  3–4 96 (27.8) 134 (20.5) 230 (23.0)
  >4 49 (14.2) 46 (7.0) 95 (9.5)
History of
  Hypertension 83 (24.1) 178 (27.2) 209 (20.9) 0.286
  Cardiovascular diseases 15 (4.4) 34 (5.2) 10 (1.0) 0.557
  Diabetes 11 (3.2) 22 (3.4) 32 (3.2) 0.886
Tobacco use 65 (19.2) 164 (25.6) 229 (23.4) 0.024
Alcohol consumption 254 (74.9) 482 (75.3) 736 (75.2) 0.894
ART, antiretroviral treatment; BMI, body mass index; Hb, haemoglobin; PJP, Pneumocystis jiroveci pneumonia.
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above 90 mm Hg or being on antihypertensive drugs (as 
per ICEA) or patient-reported hypertension.
Overall, we did not observe a difference in the propor-
tion of history on non-communicable diseases between 
the groups (hypertension, cardiovascular diseases 
or diabetes). Seventy-five per cent of the patients 
reported that alcohol consumption and tobacco use 
were more frequent in the clinic patients group as 
compared with the research cohort group (25.6% vs 
19.2%; p=0.024).
Figure 2 describes in detail the ART regimens at the 
time of enrolment in the ALT cohort. Overall, 81% of 
the patients were on first line, with the more frequent 
regimen being zidovudine plus lamivudine plus nevi-
rapine (44% of the cohort), followed by zidovudine plus 
lamivudine plus efavirenz (22%) and tenofovir plus lami-
vudine or emtricitabine plus efavirenz (10%). Of the 19% 
of the patients on second-line ART, the majority received 
ritonavir-boosted, lopinavir-based regimens (14%), and 
the remaining ones ritonavir-boosted, atazanavir-based 
regimens (5%).
After 1 year of follow-up, we observed 98.2% retention, 
with 10 patients dead, seven lost to follow-up and one 
transferred on request to another facility.
dIsCussIon
We have presented the ALT cohort, a group of 1000 patients 
on ART for 10 years and with a planned long follow-up 
period (an additional 10 years). We believe that this will be 
an important clinical research platform to understand long-
term ART outcomes such as durability of first and second 
lines and the emergence of non-communicable diseases 
among patients who have been on long-term ART. While 
there are published data from cohorts in other settings,19 20 
there is need to start collecting detailed information, partic-
ularly on non-communicable diseases and other long-
term complications from resource-limited settings and 
sub-Saharan Africa. The aim of this paper was to present 
the characteristics of this cohort as a forecast of its poten-
tial use for clinical research and potential substudies. The 
unique feature of our cohort is that the patients enrolled 
in this study have been exposed to a wide range of antiret-
roviral drugs for longer periods than most of the patients 
in sub-Saharan Africa. The analysis of data from the ALT 
cohort will provide evidence that is more generalisable to 
routine settings, as compared with that generated by clin-
ical trials, with particular emphasis on long-term outcomes 
and toxicities of patients on ART, as well as non-communi-
cable diseases and first- and second-line durability.
Figure 2 Antiretroviral treatment regimen at cohort enrolment.
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In summary, this is a cohort of patients, of whom the 
majority were female, who had severe immunosuppres-
sion at ART start, denoted by their low CD4 count and 
advanced WHO clinical stage; most of the patients were 
started on nevirapine-based regimens, combined with 
lamivudine and stavudine; of note, stavudine was phased 
out in Uganda in 2008 due to its toxicity, following a 
directive of the Ministry of Health. By the time of enrol-
ment in the ALT cohort and after 10 years on ART, the 
patients demonstrated a robust immune recovery, notably 
with more than 80% of the patients being still on first-
line drugs and with less than 5% experiencing virological 
failure.
The most common non-communicable disease 
reported was hypertension (21%), followed by diabetes 
(3%) and cardiovascular diseases (1%). One quarter of 
the participants reported tobacco use and three quarter 
alcohol consumption; unfortunately, we did not collect 
this information at the time of ART initiation.
Surprisingly, we did not find any difference in viro-
logical outcomes at cohort enrolment in patients who 
were previously monitored with exclusively CD4 count 
and with CD4 counts plus VL testing. This seems to be 
in contradiction with the extensive evidence in the liter-
ature of immunological monitoring not being enough 
sensitive or specific in identifying patients with virolog-
ical failure.21–23 It is possible that these patients, who have 
been in the continuum of care for 10 years as opposed to 
patients who drop out of care, have had good adherence 
to ART regardless of the modality of monitoring.
One strength of this cohort is the rich range of clinical 
information collected and the high quality of the gener-
ated data that we anticipate, given the high standard of 
data collection that we demonstrated in the past18 using 
our database with real-time data entry by providers.
A study limitation of this cohort is the inherent 
survival bias, whereby only patients who survived and 
were retained in care after 10 years are enrolled. Conse-
quently, these patients do not necessarily represent all 
patients started on ART in the earlier rollout of ART 
that was often characterised by severe immunological 
suppression and resulting high mortality. Survival bias 
is a common phenomenon in clinical epidemiology, 
and the study investigators will ensure that all outcomes 
from this cohort are evaluated with the correct methods, 
including but not limited to those that account for time-
varying covariates at the time of any analysis.24 On the 
other hand, the patients in the ALT cohort are likely to 
be representative of the patients who started treatment 
during the initial roll out of ART, particularly with similar 
degrees of immunosuppression25 and history of drug 
substitutions, and are currently being seeing by health-
care providers in sub-Saharan Africa.
Through collaboration with other institutions, we are 
planning for several substudies, including evaluating the 
risk for cardiovascular diseases at cohort enrolment and 
follow-up, measuring bone mineral density, screening for 
liver cirrhosis using fibroscan technology and investigating 
drug–drug interactions between ART and common drugs 
used for non-communicable diseases.
In conclusion, we envisage that the data presented as 
well the future prospective data from this study could 
contribute to increasing knowledge and improving best 
clinical care practices in resource-limited settings, partic-
ularly sub-Saharan Africa, where the roll out of ART was 
successfully implemented. This will help us to best ensure 
beneficial and sustainable patients’ clinical outcomes.
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